Royce M, et al. - Researchers investigated the efficacy of everolimus plus endocrine therapy as first-line and second-line treatment for postmenopausal women with estrogen receptor–positive, human epidermal growth receptor 2–negative advanced breast cancer. For this group of patients, everolimus plus endocrine therapy was shown to be a good first-line treatment option. This finding adds to the existing body of evidence.